Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 210 entries
Sorted by: Best Match Show Resources per page
Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules.

ACS infectious diseases

Boudreau MA, Fishovitz J, Llarrull LI, Xiao Q, Mobashery S.
PMID: 27623311
ACS Infect Dis. 2015 Oct 09;1(10):454-9. doi: 10.1021/acsinfecdis.5b00086. Epub 2015 Aug 24.

Methicillin-resistant Staphylococcus aureus (MRSA), an important human pathogen, has evolved an inducible mechanism for resistance to β-lactam antibiotics. We report herein that the integral membrane protein BlaR1, the β-lactam sensor/signal transducer protein, is phosphorylated on exposure to β-lactam antibiotics....

Cite
Boudreau MA, Fishovitz J, Llarrull LI, et al. Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules. ACS Infect Dis. 2015;1(10):454-9doi: 10.1021/acsinfecdis.5b00086.
Boudreau, M. A., Fishovitz, J., Llarrull, L. I., Xiao, Q., & Mobashery, S. (2015). Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules. ACS infectious diseases, 1(10), 454-9. https://doi.org/10.1021/acsinfecdis.5b00086
Boudreau, Marc A, et al. "Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules." ACS infectious diseases vol. 1,10 (2015): 454-9. doi: https://doi.org/10.1021/acsinfecdis.5b00086
Boudreau MA, Fishovitz J, Llarrull LI, Xiao Q, Mobashery S. Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules. ACS Infect Dis. 2015 Oct 09;1(10):454-9. doi: 10.1021/acsinfecdis.5b00086. Epub 2015 Aug 24. PMID: 27623311; PMCID: PMC5022795.
Copy Download .nbib Format: NLM
Targeted therapy of gastrointestinal stromal tumours.

World journal of gastrointestinal surgery

Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D.
PMID: 27231512
World J Gastrointest Surg. 2016 May 27;8(5):345-52. doi: 10.4240/wjgs.v8.i5.345.

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms originating in the gastrointestinal tract, usually in the stomach or the small intestine, and rarely elsewhere in the abdomen. The malignant potential of GISTs is variable ranging from small lesions with a...

Cite
Jakhetiya A, Garg PK, Prakash G, et al. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg. 2016;8(5):345-52doi: 10.4240/wjgs.v8.i5.345.
Jakhetiya, A., Garg, P. K., Prakash, G., Sharma, J., Pandey, R., & Pandey, D. (2016). Targeted therapy of gastrointestinal stromal tumours. World journal of gastrointestinal surgery, 8(5), 345-52. https://doi.org/10.4240/wjgs.v8.i5.345
Jakhetiya, Ashish, et al. "Targeted therapy of gastrointestinal stromal tumours." World journal of gastrointestinal surgery vol. 8,5 (2016): 345-52. doi: https://doi.org/10.4240/wjgs.v8.i5.345
Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg. 2016 May 27;8(5):345-52. doi: 10.4240/wjgs.v8.i5.345. PMID: 27231512; PMCID: PMC4872062.
Copy Download .nbib Format: NLM
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.

Cancer research and treatment

Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS.
PMID: 25544584
Cancer Res Treat. 2015 Apr;47(2):182-8. doi: 10.4143/crt.2013.227. Epub 2014 Sep 12.

PURPOSE: To investigate the impact of targeted treatment on direct medical costs of patients with advanced non-small cell lung cancer (NSCLC).MATERIALS AND METHODS: Medical records of 108 stage IIIB/IV NSCLC patients treated in Seoul National University Hospital between 2003...

Cite
Lee JK, Kim DW, Keam B, et al. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2014;47(2):182-8doi: 10.4143/crt.2013.227.
Lee, J. K., Kim, D. W., Keam, B., Kim, T. M., Lee, S. H., Kim, Y. J., & Heo, D. S. (2015). The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer research and treatment, 47(2), 182-8. https://doi.org/10.4143/crt.2013.227
Lee, June-Koo, et al. "The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer." Cancer research and treatment vol. 47,2 (2015): 182-8. doi: https://doi.org/10.4143/crt.2013.227
Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2015 Apr;47(2):182-8. doi: 10.4143/crt.2013.227. Epub 2014 Sep 12. PMID: 25544584; PMCID: PMC4398109.
Copy Download .nbib Format: NLM
Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.

Journal of clinical pharmacy and therapeutics

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E.
PMID: 27009771
J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23.

WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had...

Cite
Tournaire G, Despas F, Huguet F, et al. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016;41(3):360-361doi: 10.1111/jcpt.12383.
Tournaire, G., Despas, F., Huguet, F., Montastruc, J. L., & Bondon-Guitton, E. (2016). Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. Journal of clinical pharmacy and therapeutics, 41(3), 360-361. https://doi.org/10.1111/jcpt.12383
Tournaire, G, et al. "Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report." Journal of clinical pharmacy and therapeutics vol. 41,3 (2016): 360-361. doi: https://doi.org/10.1111/jcpt.12383
Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23. PMID: 27009771.
Copy Download .nbib Format: NLM
Patterns in target-directed breast cancer research.

SpringerPlus

Torres S, Simmons C, Boileau JF, McLeod D, Martins I, Trudeau M.
PMID: 26877907
Springerplus. 2016 Feb 01;5:109. doi: 10.1186/s40064-016-1736-1. eCollection 2016.

We undertake an analysis of ongoing BC targeted therapy trials registered to CT.gov to describe patterns of ongoing clinical research, highlight gaps in current research programs and identify ways of optimizing ongoing initiatives. A search of clinicaltrials.gov was conducted...

Cite
Torres S, Simmons C, Boileau JF, et al. Patterns in target-directed breast cancer research. Springerplus. 2016;5:109doi: 10.1186/s40064-016-1736-1.
Torres, S., Simmons, C., Boileau, J. F., McLeod, D., Martins, I., & Trudeau, M. (2016). Patterns in target-directed breast cancer research. SpringerPlus, 5109. https://doi.org/10.1186/s40064-016-1736-1
Torres, Sofia, et al. "Patterns in target-directed breast cancer research." SpringerPlus vol. 5 (2016): 109. doi: https://doi.org/10.1186/s40064-016-1736-1
Torres S, Simmons C, Boileau JF, McLeod D, Martins I, Trudeau M. Patterns in target-directed breast cancer research. Springerplus. 2016 Feb 01;5:109. doi: 10.1186/s40064-016-1736-1. eCollection 2016. PMID: 26877907; PMCID: PMC4735094.
Copy Download .nbib Format: NLM
Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved.

International journal of immunopathology and pharmacology

Biswas SK, Sodhi A.
PMID: 12575918
Int J Immunopathol Pharmacol. 2002 Sep-Dec;15(3):183-194. doi: 10.1177/039463200201500304.

Monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in the migration and activation of leukocytes in both physiological and pathological contexts. In this paper, we report the in vitro effect of MCP-1 on myeloid haematopoiesis. MCP-1-treated murine nonadherent bone...

Cite
Biswas SK, Sodhi A. Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved. Int J Immunopathol Pharmacol. 2002;15(3):183-194doi: 10.1177/039463200201500304.
Biswas, S. K., & Sodhi, A. (2002). Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved. International journal of immunopathology and pharmacology, 15(3), 183-194. https://doi.org/10.1177/039463200201500304
Biswas, S. K., and Sodhi, A.. "Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved." International journal of immunopathology and pharmacology vol. 15,3 (2002): 183-194. doi: https://doi.org/10.1177/039463200201500304
Biswas SK, Sodhi A. Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved. Int J Immunopathol Pharmacol. 2002 Sep-Dec;15(3):183-194. doi: 10.1177/039463200201500304. PMID: 12575918.
Copy Download .nbib Format: NLM
Anaesthetics and the rate corrected interval: learning from droperidol?.

Current opinion in anaesthesiology

Shipton EA.
PMID: 16534268
Curr Opin Anaesthesiol. 2005 Aug;18(4):419-23. doi: 10.1097/01.aco.0000168329.10067.1a.

PURPOSE OF REVIEW: Understanding of the long QT syndrome continues to evolve. Anaesthesia in patients with untreated long QT syndrome carries a risk of perioperative malignant ventricular arrhythmias. Genotypically susceptible individuals may have a normal rate-corrected QT interval and...

Cite
Shipton EA. Anaesthetics and the rate corrected interval: learning from droperidol?. Curr Opin Anaesthesiol. 2005;18(4):419-23doi: 10.1097/01.aco.0000168329.10067.1a.
Shipton, E. A. (2005). Anaesthetics and the rate corrected interval: learning from droperidol?. Current opinion in anaesthesiology, 18(4), 419-23. https://doi.org/10.1097/01.aco.0000168329.10067.1a
Shipton, Edward A. "Anaesthetics and the rate corrected interval: learning from droperidol?." Current opinion in anaesthesiology vol. 18,4 (2005): 419-23. doi: https://doi.org/10.1097/01.aco.0000168329.10067.1a
Shipton EA. Anaesthetics and the rate corrected interval: learning from droperidol?. Curr Opin Anaesthesiol. 2005 Aug;18(4):419-23. doi: 10.1097/01.aco.0000168329.10067.1a. PMID: 16534268.
Copy Download .nbib Format: NLM
Novel ocular antihypertensive compounds in clinical trials.

Clinical ophthalmology (Auckland, N.Z.)

Chen J, Runyan SA, Robinson MR.
PMID: 21629573
Clin Ophthalmol. 2011;5:667-77. doi: 10.2147/OPTH.S15971. Epub 2011 May 20.

INTRODUCTION: Glaucoma is a multifactorial disease characterized by progressive optic nerve injury and visual field defects. Elevated intraocular pressure (IOP) is the most widely recognized risk factor for the onset and progression of open-angle glaucoma, and IOP-lowering medications comprise...

Cite
Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-77doi: 10.2147/OPTH.S15971.
Chen, J., Runyan, S. A., & Robinson, M. R. (2011). Novel ocular antihypertensive compounds in clinical trials. Clinical ophthalmology (Auckland, N.Z.), 5667-77. https://doi.org/10.2147/OPTH.S15971
Chen, June, et al. "Novel ocular antihypertensive compounds in clinical trials." Clinical ophthalmology (Auckland, N.Z.) vol. 5 (2011): 667-77. doi: https://doi.org/10.2147/OPTH.S15971
Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-77. doi: 10.2147/OPTH.S15971. Epub 2011 May 20. PMID: 21629573; PMCID: PMC3104796.
Copy Download .nbib Format: NLM
Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy.

Cell division

Ullah Z, Lee CY, Depamphilis ML.
PMID: 19490616
Cell Div. 2009 Jun 02;4:10. doi: 10.1186/1747-1028-4-10.

Cyclin-dependent kinases (CDKs) play a central role in the orderly transition from one phase of the eukaryotic mitotic cell division cycle to the next. In this context, p27Kip1 (one of the CIP/KIP family of CDK specific inhibitors in mammals)...

Cite
Ullah Z, Lee CY, Depamphilis ML. Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell Div. 2009;4:10doi: 10.1186/1747-1028-4-10.
Ullah, Z., Lee, C. Y., & Depamphilis, M. L. (2009). Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell division, 410. https://doi.org/10.1186/1747-1028-4-10
Ullah, Zakir, et al. "Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy." Cell division vol. 4 (2009): 10. doi: https://doi.org/10.1186/1747-1028-4-10
Ullah Z, Lee CY, Depamphilis ML. Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell Div. 2009 Jun 02;4:10. doi: 10.1186/1747-1028-4-10. PMID: 19490616; PMCID: PMC2697143.
Copy Download .nbib Format: NLM
NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.

Analytical chemistry insights

Niwa T, Asaki T, Kimura S.
PMID: 19662183
Anal Chem Insights. 2007 Nov 14;2:93-106.

Protein kinases catalyze the transfer of the gamma-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl groups of protein side chains, and they play critical roles in regulating cellular signal transduction and other biochemical processes. They are attractive targets...

Cite
Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights. 2007;2:93-106
Niwa, T., Asaki, T., & Kimura, S. (2007). NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Analytical chemistry insights, 293-106.
Niwa, Tomoko, et al. "NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor." Analytical chemistry insights vol. 2 (2007): 93-106.
Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights. 2007 Nov 14;2:93-106. PMID: 19662183; PMCID: PMC2716809.
Copy Download .nbib Format: NLM
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

World journal of biological chemistry

Itamochi H.
PMID: 21537476
World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209.

Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage and have a poor prognosis. Currently, surgical tumor debulking, followed by platinum- and taxane-based chemotherapy is the standard...

Cite
Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010;1(7):209-20doi: 10.4331/wjbc.v1.i7.209.
Itamochi, H. (2010). Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World journal of biological chemistry, 1(7), 209-20. https://doi.org/10.4331/wjbc.v1.i7.209
Itamochi, Hiroaki. "Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action." World journal of biological chemistry vol. 1,7 (2010): 209-20. doi: https://doi.org/10.4331/wjbc.v1.i7.209
Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209. PMID: 21537476; PMCID: PMC3083967.
Copy Download .nbib Format: NLM
Staurosporine: A new tool for studying phosphatidylserine trafficking.

Communicative & integrative biology

Cho KJ, Park JH, Hancock JF.
PMID: 23986809
Commun Integr Biol. 2013 Jul 01;6(4):e24746. doi: 10.4161/cib.24746. Epub 2013 May 10.

The Ras GTPases comprising three main isoforms H-, N- and K-Ras operate at the plasma membrane as molecular switches in essential signaling pathways. Active concentration of the minor phospholipid phosphatidylserine in the inner leaflet of the plasma membrane contributes...

Cite
Cho KJ, Park JH, Hancock JF. Staurosporine: A new tool for studying phosphatidylserine trafficking. Commun Integr Biol. 2013;6(4):e24746doi: 10.4161/cib.24746.
Cho, K. J., Park, J. H., & Hancock, J. F. (2013). Staurosporine: A new tool for studying phosphatidylserine trafficking. Communicative & integrative biology, 6(4), e24746. https://doi.org/10.4161/cib.24746
Cho, Kwang-Jin, et al. "Staurosporine: A new tool for studying phosphatidylserine trafficking." Communicative & integrative biology vol. 6,4 (2013): e24746. doi: https://doi.org/10.4161/cib.24746
Cho KJ, Park JH, Hancock JF. Staurosporine: A new tool for studying phosphatidylserine trafficking. Commun Integr Biol. 2013 Jul 01;6(4):e24746. doi: 10.4161/cib.24746. Epub 2013 May 10. PMID: 23986809; PMCID: PMC3737755.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 210 entries